This view is consistent with the therapeutic failures of drug candidates that target specific AD-related molecules, such as immune therapies or inhibitors directed at β- or γ-secretases (Kikuchi et al., 2017; Moussa, 2017). This evidence concerns the gene PPIB and Alzheimer disease.